Not too late to get 'real change' to Brexit deal: Britain's Johnson

LONDON (Reuters) - Former British Foreign Minister Boris Johnson said on Sunday it was not too late for the government to get "real change" to Prime Minister Theresa May's Brexit deal and cautioned against holding another parliamentary vote on the agreement this week.

Johnson, who was a figurehead of a campaign for Britain to leave the European Union in a 2016 referendum and might influence other lawmakers on which way to vote over May's deal, asked in his column in the Telegraph newspaper whether there was a way forward to break the impasse of Brexit in parliament.

"Perhaps," he answered. "There is an EU summit this week. It is not too late to get real change to the backstop. It would be absurd to hold the vote before that has even been attempted."

He also said May should outline her strategy for talks on the future relationship with the EU to "reassure ... understandably doubtful MPs (members of parliament) by answering some basic questions".

May is expected to hold the third vote on her Brexit deal this week after suffering heavy defeats, and she is hoping to win over lawmakers, many of whom like Johnson fear the so-called Northern Irish backstop could trap Britain in the EU's sphere.

The backstop is an insurance policy to stop any return of a border controls between the British province of Northern Ireland and EU member Ireland if a future trading deal fails to remove the need for them.

(Reporting by Elizabeth Piper; Editing by Cynthia Osterman)

Must Read

She said yes: Claye proposes after taking Olympic silver

Aug 16, 2016

She said yes: Claye proposes after taking Olympic silver

Conventional tax proposals in an unconventional US campaign

Aug 17, 2016

In this unconventional campaign season, Donald Trump and Hillary Clinton have produced two conventional tax plans that mostly track their parties' long-standing views

Patent for J&J's Remicade invalidated, cheaper version looms

Aug 17, 2016

A cheaper version of Johnson & Johnson's top-selling drug, the rheumatoid arthritis treatment Remicade, could be available in the U.S. two years early after a federal judge ruled a key patent on the drug invalid

Search

Obserworld delivers the most accurate and up-to-date world news for the global audience with a thorough research and in-depth interviews. Discover the world through Obserworld.

Contact us: sales[at]obserworld.com